SZLSFStagezero Life SciencesSZLSF info
$0.08info0.00%24h
Global rank32784
Market cap$9.82M
Change 7d-
YTD Performance172.11%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    Stagezero Life Sciences (SZLSF) Stock Overview

    StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

    SZLSF Stock Information

    Symbol
    SZLSF
    Address
    70 East Beaver Creek RoadRichmond Hill, ON L4B 3B2Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.stagezerolifesciences.com
    Country
    πŸ‡¨πŸ‡¦ Canada
    Phone Number

    Stagezero Life Sciences (SZLSF) Price Chart

    -
    Value:-

    Stagezero Life Sciences Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.08
    N/A
    Market Cap
    $9.82M
    N/A
    Shares Outstanding
    122.72M
    N/A
    Employees
    40.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org